Vericel (VCEL) Cut to Sell at Zacks Investment Research

Zacks Investment Research lowered shares of Vericel (NASDAQ:VCEL) from a hold rating to a sell rating in a research note released on Saturday morning, Zacks.com reports.

According to Zacks, “Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States. “

Several other brokerages have also issued reports on VCEL. BidaskClub lowered Vericel from a buy rating to a hold rating in a research note on Friday, March 15th. Needham & Company LLC lowered Vericel from a buy rating to a hold rating and set a $17.92 price objective on the stock. in a research report on Thursday, February 28th. Finally, Oppenheimer boosted their price objective on Vericel from $23.00 to $32.00 and gave the stock an outperform rating in a research report on Wednesday, May 8th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $22.98.



Shares of VCEL opened at $16.85 on Friday. Vericel has a 52-week low of $8.95 and a 52-week high of $21.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 7.38 and a current ratio of 8.47. The firm has a market capitalization of $739.90 million, a PE ratio of -120.36 and a beta of 2.93.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.07). Vericel had a negative return on equity of 3.40% and a negative net margin of 3.51%. The company had revenue of $21.81 million for the quarter, compared to analyst estimates of $22.51 million. During the same quarter last year, the company posted ($0.21) EPS. The company’s revenue for the quarter was up 21.0% compared to the same quarter last year. Equities research analysts expect that Vericel will post 0.06 earnings per share for the current year.

In related news, CFO Gerard J. Michel sold 15,625 shares of the business’s stock in a transaction on Monday, April 8th. The stock was sold at an average price of $17.64, for a total transaction of $275,625.00. Following the sale, the chief financial officer now owns 127,047 shares in the company, valued at approximately $2,241,109.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Steven C. Gilman sold 7,500 shares of the business’s stock in a transaction on Thursday, February 28th. The stock was sold at an average price of $18.02, for a total value of $135,150.00. The disclosure for this sale can be found here. Insiders have sold a total of 58,125 shares of company stock worth $1,034,900 in the last 90 days. 4.50% of the stock is currently owned by corporate insiders.

A number of hedge funds have recently modified their holdings of VCEL. Doyle Wealth Management bought a new stake in Vericel during the 4th quarter worth $35,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Vericel during the 4th quarter worth about $44,000. Financial Architects Inc acquired a new position in Vericel during the 4th quarter worth about $69,000. Pearl River Capital LLC acquired a new position in Vericel during the 1st quarter worth about $72,000. Finally, Great West Life Assurance Co. Can acquired a new position in Vericel during the 4th quarter worth about $78,000. Institutional investors and hedge funds own 83.14% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

See Also: The role of implied volatility with call option volume

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.